[go: up one dir, main page]

ECSP12012106A - Terapia antiviral - Google Patents

Terapia antiviral

Info

Publication number
ECSP12012106A
ECSP12012106A ECSP12012106A ECSP12012106A EC SP12012106 A ECSP12012106 A EC SP12012106A EC SP12012106 A ECSP12012106 A EC SP12012106A EC SP12012106 A ECSP12012106 A EC SP12012106A
Authority
EC
Ecuador
Prior art keywords
antiviral therapy
hiv
combinations
treatment
aids
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Richard Underwood
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ECSP12012106A publication Critical patent/ECSP12012106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a combinaciones de los compuestos que comprenden inhibidores de la integrasa de VIH y otros agentes terapéuticos. Estas combinaciones son útiles en la inhibición de la réplica del VIH, la prevención y/o el tratamiento de la infección por VIH, y en el tratamiento de SIDA y/o ARC.
ECSP12012106 2010-01-27 2012-08-14 Terapia antiviral ECSP12012106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
ECSP12012106A true ECSP12012106A (es) 2013-05-31

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012106 ECSP12012106A (es) 2010-01-27 2012-08-14 Terapia antiviral

Country Status (45)

Country Link
US (13) US20120295898A1 (es)
EP (6) EP3127542B1 (es)
JP (9) JP2013518107A (es)
KR (4) KR101964923B1 (es)
CN (2) CN105311033B (es)
AP (1) AP3551A (es)
AU (1) AU2011209788C1 (es)
BR (1) BR112012018670A2 (es)
CA (4) CA2967453C (es)
CL (1) CL2012002080A1 (es)
CO (1) CO6602152A2 (es)
CR (1) CR20120423A (es)
CY (6) CY1116509T1 (es)
DK (4) DK2932970T3 (es)
DO (2) DOP2012000205A (es)
EA (4) EA037601B1 (es)
EC (1) ECSP12012106A (es)
ES (4) ES2969969T3 (es)
FI (2) FI3494972T3 (es)
FR (2) FR18C1043I2 (es)
HK (1) HK1250335A1 (es)
HR (4) HRP20150770T1 (es)
HU (6) HUE065569T2 (es)
IL (5) IL221007A (es)
LT (5) LT3127542T (es)
LU (1) LUC00090I2 (es)
MA (1) MA34002B1 (es)
ME (2) ME02182B (es)
MX (4) MX367937B (es)
MY (3) MY188334A (es)
NO (2) NO2932970T3 (es)
NZ (4) NZ601319A (es)
PE (2) PE20160180A1 (es)
PH (3) PH12012501537A1 (es)
PL (4) PL3127542T3 (es)
PT (4) PT2932970T (es)
RS (4) RS65183B1 (es)
SG (3) SG10201707183TA (es)
SI (4) SI3127542T1 (es)
SM (4) SMT201800290T1 (es)
TN (1) TN2012000376A1 (es)
TR (1) TR201807704T4 (es)
UA (1) UA105556C2 (es)
WO (1) WO2011094150A1 (es)
ZA (1) ZA201205586B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
NZ706223A (en) 2012-10-23 2018-11-30 Cipla Ltd Pharmaceutical antiretroviral composition
PE20151499A1 (es) 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
CA2897137A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (es) 2013-07-12 2018-07-21
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
IN2014MU00916A (es) 2014-03-20 2015-09-25 Cipla Ltd
EP3151920B1 (en) 2014-06-04 2025-08-06 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (es) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP6603306B2 (ja) 2014-07-29 2019-11-06 レツク・フアーマシユーテイカルズ・デー・デー ドルテグラビルナトリウムの新規な水和物
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
EP3334419A1 (en) * 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
JP7384783B2 (ja) 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
MX2020003377A (es) * 2017-10-13 2020-09-28 Viiv Healthcare Co Formulacion de tableta farmaceutica de dos capas.
TW202544011A (zh) 2019-03-22 2025-11-16 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ感染症を治療するための四環式化合物及びその使用
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU727983B2 (en) * 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
AU784782B2 (en) 2000-01-31 2006-06-15 Cook Biotech, Incorporated Stent valves and uses of same
BRPI0208811B8 (pt) 2001-04-10 2021-05-25 Pfizer derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CN1302779C (zh) * 2002-06-27 2007-03-07 美迪维尔公司 含有阿巴卡韦和阿洛夫定的药物制剂及其用途
EA201100293A1 (ru) * 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1720856B1 (en) * 2004-02-11 2013-08-14 GlaxoSmithKline LLC Hiv integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
EP1742642B1 (en) * 2004-04-14 2008-10-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1930011B1 (en) 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
ATE479693T1 (de) 2004-09-17 2010-09-15 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
BRPI0610030B8 (pt) * 2005-04-28 2022-01-11 Glaxosmithkline Llc Composto, composição farmacêutica, e, uso de um composto
CA2610029A1 (en) 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a quinoline compound and other hiv infection therapeutic agents
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
SG170795A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP5754005B2 (ja) * 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
PT2069303E (pt) 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
NZ575831A (en) 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
PL2487161T5 (pl) 2007-02-23 2024-09-09 Gilead Sciences, Inc. <div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
EA200971115A1 (ru) 2007-06-29 2010-04-30 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новые ингибиторы обратной транскриптазы вич
CA2692331A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
EP2217573A4 (en) 2007-11-01 2011-08-31 Uab Research Foundation TREATMENT AND PREVENTION OF VIRUS INFECTIONS
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
JP2011508748A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
MX2010007374A (es) 2008-01-03 2010-10-05 Virochem Pharma Inc Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
AU2008346823B2 (en) 2008-01-04 2015-03-12 Gilead Sciences, Inc. Inhibitors of cytochrome P450
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
DK2320908T3 (en) * 2008-07-25 2014-03-10 Viiv Healthcare Co DOLUTEGRAVIR prodrugs
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
JP5086478B2 (ja) 2008-12-11 2012-11-28 塩野義製薬株式会社 カルバモイルピリドンｈｉｖインテグラーゼ阻害剤及びそれらの中間体の合成
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
AU2012236332A1 (en) 2011-04-01 2013-10-31 Chiesi Farmaceutici S.P.A. Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
HRP20180855T1 (hr) 2018-06-29
FR24C1024I2 (fr) 2025-06-27
PE20121524A1 (es) 2012-12-03
HRP20181531T1 (hr) 2018-11-16
RS65183B1 (sr) 2024-03-29
SI2531027T1 (sl) 2015-08-31
DK2932970T3 (en) 2018-05-28
IL281959A (en) 2021-05-31
PL2932970T3 (pl) 2018-08-31
CY1116509T1 (el) 2017-03-15
HK1250335A1 (en) 2018-12-14
MY202778A (en) 2024-05-21
IL267658A (en) 2019-08-29
EP2531027B1 (en) 2015-05-06
KR101964923B1 (ko) 2019-04-02
LTPA2018013I1 (lt) 2018-11-12
SMT201800594T1 (it) 2019-01-11
ME02182B (me) 2015-10-20
HUE037812T2 (hu) 2018-09-28
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
KR20160111536A (ko) 2016-09-26
CO6602152A2 (es) 2013-01-18
US20170216284A1 (en) 2017-08-03
EP2531027A4 (en) 2013-07-03
US20170079982A1 (en) 2017-03-23
SMT201500177B (it) 2015-09-07
EP2932970B1 (en) 2018-03-21
PL3127542T3 (pl) 2019-03-29
JP2016145204A (ja) 2016-08-12
CY2024017I2 (el) 2025-05-09
WO2011094150A1 (en) 2011-08-04
CA3003988C (en) 2020-01-07
MX356891B (es) 2018-06-19
KR20120128640A (ko) 2012-11-27
PH12012501537A1 (en) 2018-02-07
LTC2932970I2 (lt) 2022-04-25
EP3127542B1 (en) 2018-08-22
EP2932970A1 (en) 2015-10-21
SG10201509476RA (en) 2015-12-30
LTC3494972I2 (es) 2025-11-10
ME03058B (me) 2019-01-20
SI3127542T1 (sl) 2018-11-30
JP2013518107A (ja) 2013-05-20
CA3060290A1 (en) 2011-08-04
DK2531027T3 (en) 2015-07-20
NZ627827A (en) 2016-02-26
LTPA2024516I1 (es) 2024-06-25
PH12018502489A1 (en) 2020-06-15
PH12016500195A1 (en) 2016-12-05
EA025176B1 (ru) 2016-11-30
SMT202400063T1 (it) 2024-03-13
TN2012000376A1 (en) 2014-01-30
HUE040554T2 (hu) 2019-03-28
EP3494972A1 (en) 2019-06-12
DOP2012000205A (es) 2012-10-15
NZ627824A (en) 2016-02-26
EP4316599A2 (en) 2024-02-07
PT3494972T (pt) 2024-02-12
NO2018036I1 (no) 2018-10-15
EA037601B1 (ru) 2021-04-20
US20210401850A1 (en) 2021-12-30
PT3127542T (pt) 2018-11-26
JP2021091705A (ja) 2021-06-17
US20180098992A1 (en) 2018-04-12
JP2022071126A (ja) 2022-05-13
MY188334A (en) 2021-11-30
FIC20240016I1 (fi) 2024-05-31
ES2543066T3 (es) 2015-08-14
HK1179522A1 (en) 2013-10-04
EA202190473A3 (ru) 2021-12-31
JP6268386B2 (ja) 2018-01-31
US20200230147A1 (en) 2020-07-23
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
CA3003988A1 (en) 2011-08-04
CY1120457T1 (el) 2019-07-10
BR112012018670A2 (pt) 2018-02-06
CA2967453A1 (en) 2011-08-04
JP7724619B2 (ja) 2025-08-18
SI3494972T1 (sl) 2024-03-29
ES2670811T3 (es) 2018-06-01
EA201290583A1 (ru) 2013-04-30
EA201892277A1 (ru) 2019-03-29
CN102791129B (zh) 2015-09-30
AU2011209788A1 (en) 2012-08-16
KR101883750B1 (ko) 2018-07-31
CN105311033A (zh) 2016-02-10
PH12016500195B1 (en) 2021-08-04
EA202190473A2 (ru) 2021-06-30
CY2024017I1 (el) 2025-05-09
MX367937B (es) 2019-09-12
IL281959B (en) 2021-12-01
AP2012006445A0 (en) 2012-08-31
CN102791129A (zh) 2012-11-21
AP3551A (en) 2016-01-18
US20160199379A1 (en) 2016-07-14
CN105311033B (zh) 2019-05-07
LT2932970T (lt) 2018-06-25
JP2023085431A (ja) 2023-06-20
HUS2400017I1 (hu) 2024-06-28
UA105556C2 (uk) 2014-05-26
US20160339033A1 (en) 2016-11-24
AU2011209788C1 (en) 2014-08-28
DK3494972T3 (da) 2024-01-29
JP2018127473A (ja) 2018-08-16
DOP2021000147A (es) 2022-01-16
SI2932970T1 (en) 2018-07-31
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
MA34002B1 (fr) 2013-02-01
LT3127542T (lt) 2018-11-26
KR20170078868A (ko) 2017-07-07
LUC00090I2 (es) 2019-01-08
CA2787691A1 (en) 2011-08-04
PL2531027T3 (pl) 2016-01-29
HRP20150770T1 (hr) 2015-08-28
LT3494972T (lt) 2024-03-12
NZ627826A (en) 2016-01-29
HUE065569T2 (hu) 2024-06-28
IL221007A0 (en) 2012-09-24
FR18C1043I1 (es) 2018-11-30
HUE026849T2 (en) 2016-08-29
US20170119777A1 (en) 2017-05-04
EA032868B1 (ru) 2019-07-31
PT2932970T (pt) 2018-06-08
US20120295898A1 (en) 2012-11-22
AU2011209788B2 (en) 2014-02-06
EP3494972B1 (en) 2023-12-13
US20250017939A1 (en) 2025-01-16
IL245182A0 (en) 2016-06-30
EP2531027A1 (en) 2012-12-12
US20180200254A1 (en) 2018-07-19
EA201690872A3 (ru) 2016-12-30
EP4316599A3 (en) 2024-04-10
FI3494972T3 (fi) 2024-03-01
NZ601319A (en) 2014-08-29
CL2012002080A1 (es) 2012-11-30
CA3060290C (en) 2022-07-12
EP3351249A1 (en) 2018-07-25
JP2017008087A (ja) 2017-01-12
JP2019167371A (ja) 2019-10-03
ES2969969T3 (es) 2024-05-23
SG10201707183TA (en) 2017-10-30
CA2967453C (en) 2018-07-17
CY1121040T1 (el) 2019-12-11
PL3494972T3 (pl) 2024-05-27
DK3127542T3 (en) 2018-11-12
IL245182B (en) 2018-04-30
CA2787691C (en) 2018-07-17
MX367938B (es) 2019-09-12
CY2018029I1 (el) 2019-07-10
TR201807704T4 (tr) 2018-06-21
US11234985B2 (en) 2022-02-01
CR20120423A (es) 2012-11-22
IL267658B (en) 2021-04-29
PT2531027E (pt) 2015-09-16
HUS1800042I1 (hu) 2018-11-28
US20150238496A1 (en) 2015-08-27
RS54123B1 (sr) 2015-12-31
FR18C1043I2 (fr) 2019-10-11
IL257267A (en) 2018-03-29
EA201690872A2 (ru) 2016-08-31
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
RS57728B1 (sr) 2018-12-31
KR101830715B1 (ko) 2018-04-04
HK1209629A1 (en) 2016-04-08
US20170281636A1 (en) 2017-10-05
CY1126771T1 (el) 2025-05-09
EP3127542A1 (en) 2017-02-08
SMT201800290T1 (it) 2018-07-17
ES2688925T3 (es) 2018-11-07
MY207233A (en) 2025-02-07
US10426780B2 (en) 2019-10-01
NO2932970T3 (es) 2018-08-18
MX2012008774A (es) 2012-08-17
JP2025131664A (ja) 2025-09-09
KR20180078358A (ko) 2018-07-09

Similar Documents

Publication Publication Date Title
ECSP12012106A (es) Terapia antiviral
CY1125202T1 (el) Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο hiv
EA201391108A1 (ru) Лечение липодистрофии
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
ECSP13012418A (es) Derivados de ácido 2-quinolin-acético como compuestos antivirales para vih
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2017010623A (es) Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral.
GEAP202014873A (en) Methods for treatment and prophylaxis of hiv and aids
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
CO6630124A2 (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?